ZEALAND PHARMA/S (NASDAQ:ZEAL) Receives Consensus Rating of “Buy” from Analysts

Shares of ZEALAND PHARMA/S (NASDAQ:ZEAL) have been assigned a consensus recommendation of “Buy” from the seven analysts that are presently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $29.00.

Several equities analysts recently issued reports on the company. ValuEngine raised ZEALAND PHARMA/S from a “sell” rating to a “hold” rating in a report on Friday, March 15th. Zacks Investment Research cut Inflarx from a “buy” rating to a “hold” rating in a report on Friday, May 3rd.

A hedge fund recently bought a new stake in ZEALAND PHARMA/S stock. OLD Mission Capital LLC purchased a new stake in ZEALAND PHARMA/S (NASDAQ:ZEAL) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 17,466 shares of the company’s stock, valued at approximately $203,000. OLD Mission Capital LLC owned 0.06% of ZEALAND PHARMA/S at the end of the most recent quarter. 9.08% of the stock is currently owned by institutional investors and hedge funds.

Shares of ZEAL stock traded up $0.30 during midday trading on Friday, hitting $22.28. The company had a trading volume of 1,883 shares, compared to its average volume of 12,822. The stock has a 50 day simple moving average of $21.25. ZEALAND PHARMA/S has a 52-week low of $11.51 and a 52-week high of $23.04. The firm has a market capitalization of $662.54 million, a PE ratio of 7.39 and a beta of 1.90.

ZEALAND PHARMA/S (NASDAQ:ZEAL) last posted its quarterly earnings results on Thursday, May 16th. The company reported ($0.63) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.18) by ($0.45). As a group, research analysts forecast that ZEALAND PHARMA/S will post -2.1 earnings per share for the current fiscal year.


Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.

Read More: What can cause a stock to outperform?

Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.